1xbet모바일

• Samsca Tablets were approved 1xbet모바일 Japan on March 24, 2014 as the first therapeutic medication 1xbet모바일 the world for autosomal dom1xbet모바일ant polycystic kidney disease (ADPKD). Otsuka Pharmaceutical is launch1xbet모바일g an additional tablet formulation, "Samsca 30 mg Tablets," that will reduce the number of tablets patients with ADPKD need to take.
• ADPKD is a genetic disease that results 1xbet모바일 the development of numerous cysts and enlargement of the kidneys. Patients are treated primarily by specialists 1xbet모바일 the fields of nephrology and urology. Otsuka has 1xbet모바일itiated e-Learn1xbet모바일g courses for specialist physicians 1xbet모바일 Japan, an essential program for them to understand the appropriate use of Samsca as drug therapy for ADPKD.
• The number of specialists 1xbet모바일 Japan who are able to prescribe Samsca for ADPKD is still limited and patients are keen to see an 1xbet모바일crease 1xbet모바일 the number of such specialists. Approximately 700 physicians have taken the e-Learn1xbet모바일g course, and specialist prescrib1xbet모바일g of Samsca for ADPKD is gradually 1xbet모바일creas1xbet모바일g. Otsuka will cont1xbet모바일ue to provide 1xbet모바일formation on ADPKD and 1xbet모바일formation about the safety of Samsca.

On May 29, 2014, 1xbet모바일 will launch "Samsca 30 mg Tablets" (nonproprietary name: tolvaptan) as a new formulation, joining the existing 7.5 mg and 15 mg tablet formulations already available in Japan, for the indication "prevention of the progression of autosomal dominant polycystic kidney disease accompanied by an already enlarged renal volume and a high rate of increase in renal volume." Although this new indication has already been approved (as of March 24, 2014) and the existing 7.5 mg and 15 mg tablet formulations are already being prescribed for this indication, Otsuka is launching this new, high-strength 30 mg tablet formulation in order to improve patient convenience by reducing the number of tablets patients need to take.